Merck Plows Ahead With Another Suit Over Diabetes Drug

Law360 (November 5, 2020, 4:17 PM EST) -- Merck has filed a lawsuit in Delaware federal court seeking to block Indian drugmaker Ajanta Pharma from moving ahead with plans to sell a generic version of a diabetes drug that Merck says would infringe a patent it owns.

Mumbai-based Ajanta Pharma Ltd. can't proceed with its abbreviated new drug application, or ANDA, to market a generic version of diabetes drug Janumet before the patent expires, the New Jersey-based pharmaceutical giant said in the complaint filed Wednesday. The suit, one of several Merck has filed over the patent in the last year, also names Ajanta Pharma USA Inc., the company's New...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!